文献速递白血病

IKZF1plus定义儿童B细胞前体急性淋巴细胞白血病中一种新的依赖微小残留病的极差预后特征

IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
PubMed 文献 · J Clin Oncol · 2018-03-02

该研究在AIEOP-BFM ALL 2000试验的991例儿童B细胞前体急性淋巴细胞白血病患者中分析IKZF1缺失与共缺失的预后影响,发现IKZF1plus(IKZF1缺失合并CDKN2A、CDKN2B、PAX5或PAR1缺失且无ERG缺失)占6%,5年无事件生存率53±6%,显著低于非IKZF1plus的IKZF1缺失患者(79±5%)和无IKZF1缺失者(87±1%)。该预后效应在微小残留病分层后差异显著,结论在417例复制队列中得以确认。

要点

  • IKZF1plus占B细胞前体急性淋巴细胞白血病的6%,5年无事件生存率53±6%,预后极差。
  • IKZF1plus的预后效应依赖于诱导治疗后微小残留病水平,标准风险者5年无事件生存率94±5%。
  • 当前AIEOP-BFM方案对微小残留病阳性的IKZF1plus患者效果不佳,需新实验性治疗。

核心结论

  • IKZF1plus描述了儿童B细胞前体急性淋巴细胞白血病中一种新的依赖微小残留病的极差预后特征。

研究设计与样本

  • 分析纳入AIEOP-BFM ALL 2000试验中991例具有IKZF1、PAX5、ETV6、RB1、BTG1、EBF1、CDKN2A、CDKN2B、PAR1区域(CRLF2、CSF2RA、IL3RA)和ERG拷贝数变异完整信息的B细胞前体急性淋巴细胞白血病患者。
  • 复制分析纳入同一试验的417例患者。

主要发现

  • IKZF1plus组占B细胞前体急性淋巴细胞白血病的6%,5年无事件生存率为53±6%,而非IKZF1plus的IKZF1缺失患者为79±5%,无IKZF1缺失患者为87±1%(P≤.001)。
  • IKZF1plus组、非IKZF1plus的IKZF1缺失组和无IKZF1缺失组的5年累积复发率分别为44±6%、11±4%和10±1%(P≤.001)。
  • 多变量分析显示IKZF1plus的预后效应独立,且在复制队列中得到确认。
  • 按诱导治疗后微小残留病水平分层,微小残留病标准风险的IKZF1plus患者5年无事件生存率为94±5%,中危者为40±10%,高危者为30±14%(P≤.001)。
  • 对应5年累积复发率分别为6±6%、60±10%和60±17%(P≤.001)。

关键数值与推荐

  • IKZF1plus定义为IKZF1缺失与CDKN2A、CDKN2B、PAX5或PAR1缺失共存,且无ERG缺失。

临床怎么用

  • 作者指出当前AIEOP-BFM治疗对微小残留病阳性的IKZF1plus患者 largely 无效,将在即将开展的AIEOP-BFM ALL 2017试验中评估新的实验性治疗方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Somatic deletions that affect the lymphoid transcription factor-coding gene IKZF1 have previously been reported as independently associated with a poor prognosis in pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). We have now refined the prognostic strength of IKZF1 deletions by analyzing the effect of co-occurring deletions. Patients and Methods The analysis involved 991 patients with BCP ALL treated in the Associazione Italiana Ematologia ed Oncologia Pediatrica-Berlin-Frankfurt-Muenster (AIEOP-BFM) ALL 2000 trial with complete information for copy number alterations of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, Xp22.33/Yp11.31 (PAR1 region; CRLF2, CSF2RA, and IL3RA), and ERG; replication of findings involved 417 patients from the same trial. Results IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion conferred the worst outcome and, consequently, were grouped as IKZF1plus. The IKZF1plus group comprised 6% of patients with BCP ALL, with a 5-year event-free survival of 53 ± 6% compared with 79 ± 5% in patients with IKZF1 deletion who did not fulfill the IKZF1plus definition and 87 ± 1% in patients who lacked an IKZF1 deletion ( P ≤ .001). Respective 5-year cumulative relapse incidence rates were 44 ± 6%, 11 ± 4%, and 10 ± 1% ( P ≤ .001). Results were confirmed in the replication cohort, and multivariable analyses demonstrated independence of IKZF1plus. The IKZF1plus prognostic effect differed dramatically in analyses stratified by minimal residual disease (MRD) levels after induction treatment: 5-year event-free survival for MRD standard-risk IKZF1plus patients was 94 ± 5% versus 40 ± 10% in MRD intermediate- and 30 ± 14% in high-risk IKZF1plus patients ( P ≤ .001). Corresponding 5-year cumulative incidence of relapse rates were 6 ± 6%, 60 ± 10%, and 60 ± 17% ( P ≤ .001). Conclusion IKZF1plus describes a new MRD-dependent very-poor prognostic profile in BCP ALL. Because current AIEOP-BFM treatment is largely ineffective for MRD-positive IKZF1plus patients, new experimental treatment approaches will be evaluated in our upcoming trial AIEOP-BFM ALL 2017.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Stanulla M, Dagdan E, Zaliova M, et al. IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Oncol. 2018. PMID: 29498923. doi:10.1200/JCO.2017.74.3617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。